Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OUS Approvals Analysis: Small Companies Dominate International Approvals In April

Executive Summary

April was a return to a more typical volume of medical device approvals outside the US after a particularly busy March. And the big names in medtech were mostly quiet in April's OUS approvals, according to Medtech Insight's Approval Tracker.


Related Content

Starts & Stops: New Trial Starts Led By Peripheral Vascular Interventions
US Approvals Analysis: April A Big Month For Non-Invasive Neurostim
Stent Leaders Pull Out Of India Amidst Price Cap Storm; Opportunity For 'The Dragon'?
Starts & Stops: ICS' Emblok Medtronic's Arctic Front, Abbott's Absorb, Boston Scientific's S-ICD
OUS Approvals: Edwards And Trinity Lead Spring Surge
OUS Approvals Analysis: Medtronic Records Another Stack Of Overseas Approvals
OUS Approvals Analysis: BSX, Edwards Score New CE Marks In TAVR Battlefield; Chinese DES Advances In Asia
Robert Byrne: Absorb, Synergy, And The Future Of Coronary Stents
EuroPCR Stent Wrap-Up: Biotronik’s Magmaris magnesium stent, Reva’s Fantom Polymer DES, and Elixir’s DESolve


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts